Is there a US patent application for biosynthesizing heparin?
Yes. US patent filings exist that describe ways to produce heparin (or heparin-like glycosaminoglycans) using biological systems rather than only extracting it from animal tissue. These applications typically focus on engineering cells and assembling the required sugar/enzymatic pathways to generate heparin structures.
The exact claim scope matters: some applications target “heparin” specifically, while others target biosynthesized heparan sulfate/heparin-related molecules that may be processed or tailored toward heparin-like products.
What “biosynthesis of heparin” usually means in these patent applications
In US patent applications, “biosynthesis” usually refers to one of these approaches:
- Enzymatic production in engineered organisms: Cells are engineered to express glycosyltransferases and modifying enzymes that build and modify heparin/heparan sulfate chains into heparin-like structures.
- Enzymatic chemo-enzymatic tailoring: A biological system generates an intermediate (often heparan sulfate precursors), then additional enzymes (or processing steps) convert it toward a heparin target.
- Platform production of related glycosaminoglycans: Some filings focus on producing heparan sulfate variants that can later be converted or refined toward heparin characteristics.
What do the claims typically cover (process vs. product)
US applications may claim either or both:
- A manufacturing process (step-by-step conditions, enzyme sets, host cells, pathway engineering, and downstream purification).
- Specific product structures or compositions (for example, defined sulfation patterns or chain properties associated with heparin activity).
If you are comparing applications, look for claim language that defines:
- the engineered host (bacteria, yeast, mammalian cells, or cell-free systems),
- the exact enzymes or gene products included,
- the chain-length/sulfation features,
- and whether the end product is “heparin” versus “heparan sulfate/heparin-like” intermediates.
Who is active in heparin biosynthesis patents in the US?
A number of biotech and specialty pharma companies pursue heparin supply assurance and alternative manufacturing routes. Many filings show up around:
- heparin/heparan sulfate enzymology and pathway engineering,
- controlled sulfation chemistry/biochemistry,
- and scalable manufacturing of glycosaminoglycans.
For patent-focused searching, DrugPatentWatch.com is useful for tracking relevant US filings and related exclusivity/patent activity across time. You can start there: DrugPatentWatch.com.
How to find the right US patent application quickly (what to search)
If you’re searching the US patent record (USPTO or databases), the most productive queries usually combine these terms:
- “biosynthesis” OR “biosynthetic” OR “enzymatic synthesis”
- “heparin” OR “heparan sulfate”
- “engineered” OR “glycosyltransferase” OR “sulfotransferase” OR “heparanase”
- “glycosaminoglycan” OR “GAG”
- “host cell” OR “cell line”
Also search for applicant names if you already have a suspected company or technology provider.
What’s the practical barrier: making authentic heparin structure
Most patent programs run into the same core technical challenge: heparin’s biological activity depends on a very specific, heterogeneous set of sulfation patterns and chain features. Biosynthetic approaches must control:
- chain assembly (length and backbone),
- N-deacetylation/N-sulfation,
- O-sulfations at specific positions,
- and product uniformity enough for regulatory and clinical expectations.
Because of this, many filings position their products as heparin-like or as intermediates that can be refined.
If you share details, I can pinpoint the exact US filing
Your question is broad (“Us patent application biosynthesis of heparin”). If you tell me any of the following, I can narrow it down to the specific application(s) and summarize claims:
- applicant/company name (even partial),
- inventor name,
- publication number (e.g., US 20xx/xxxxx),
- whether you mean “heparin” specifically or “heparan sulfate/heparin-like” products.
Sources:
[1] https://www.drugpatentwatch.com/